As of the latest Form 4 filed Jul 2, 2026.
What Spyre Therapeutics Inc. insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 40 most recent filings for SYRE.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-02 | 2026-07-01 | Burrows Scott L Chief Financial Officer | SSale | −1.73K | $88.37 | $152K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Burrows Scott L, Chief Financial Officer | SSale | −5.78K | $87.55 | $506K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Burrows Scott L, Chief Financial Officer | MExercise | +7.50K | $14.50 | $109K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Sloan Sheldon Chief Medical Officer | SSale | −1.83K | $88.34 | $162K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Sloan Sheldon, Chief Medical Officer | SSale | −6.50K | $87.52 | $569K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Sloan Sheldon, Chief Medical Officer | MExercise | +8.33K | $27.46 | $229K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Turtle Cameron Chief Executive Officer | SSale | −590.00 | $88.91 | $52.5K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Turtle Cameron, Chief Executive Officer | SSale | −4.23K | $88.12 | $373K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Turtle Cameron, Chief Executive Officer | SSale | −10.2K | $87.44 | $890K | Yes (planned) | Form 4 ↗ |
| 2026-06-26 | 2026-06-25 | Burrows Scott L Chief Financial Officer | SSale | −10.0K | $87.14 | $871K | No | Form 4 ↗ |
| 2026-06-26 | 2026-06-25 | Burrows Scott L, Chief Financial Officer | SSale | −5.00K | $87.12 | $436K | No | Form 4 ↗ |
| 2026-06-26 | 2026-06-25 | Burrows Scott L, Chief Financial Officer | MExercise | +15.0K | $14.50 | $218K | No | Form 4 ↗ |
| 2026-06-23 | 2026-06-23 | Fairmount Funds Management LLC Director | SSale | −4.68M | $85.31 | $400M | No | Form 4 ↗ |
| 2026-06-23 | 2026-06-23 | Fairmount Funds Management LLC, Director | CConvert | +667K | — | — | No | Form 4 ↗ |
| 2026-06-23 | 2026-06-22 | HENDERSON MICHAEL THOMAS Director | SSale | −20.0K | $100.00 | $2.00M | Yes (planned) | Form 4 ↗ |
| 2026-06-03 | 2026-06-03 | Sloan Sheldon Chief Medical Officer | SSale | −8.33K | $75.00 | $625K | Yes (planned) | Form 4 ↗ |
| 2026-06-03 | 2026-06-03 | Sloan Sheldon, Chief Medical Officer | MExercise | +8.33K | $27.46 | $229K | Yes (planned) | Form 4 ↗ |
| 2026-06-03 | 2026-06-01 | Turtle Cameron Chief Executive Officer | SSale | −3.29K | $71.38 | $235K | Yes (planned) | Form 4 ↗ |
| 2026-06-03 | 2026-06-01 | Turtle Cameron, Chief Executive Officer | SSale | −8.15K | $70.50 | $575K | Yes (planned) | Form 4 ↗ |
| 2026-06-03 | 2026-06-01 | Turtle Cameron, Chief Executive Officer | SSale | −3.56K | $69.40 | $247K | Yes (planned) | Form 4 ↗ |
| 2026-06-03 | 2026-06-01 | Burrows Scott L Chief Financial Officer | SSale | −3.10K | $72.06 | $223K | Yes (planned) | Form 4 ↗ |
| 2026-06-03 | 2026-06-01 | Burrows Scott L, Chief Financial Officer | SSale | −2.60K | $70.77 | $184K | Yes (planned) | Form 4 ↗ |
| 2026-06-03 | 2026-06-01 | Burrows Scott L, Chief Financial Officer | SSale | −1.80K | $69.75 | $126K | Yes (planned) | Form 4 ↗ |
| 2026-06-03 | 2026-06-01 | Burrows Scott L, Chief Financial Officer | MExercise | +7.50K | $14.50 | $109K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Sloan Sheldon Chief Medical Officer | SSale | −400.00 | $75.37 | $30.1K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Sloan Sheldon, Chief Medical Officer | SSale | −5.06K | $74.60 | $377K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Sloan Sheldon, Chief Medical Officer | SSale | −10.4K | $73.74 | $764K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Sloan Sheldon, Chief Medical Officer | SSale | −12.8K | $72.94 | $932K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Sloan Sheldon, Chief Medical Officer | SSale | −8.78K | $71.56 | $628K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Sloan Sheldon, Chief Medical Officer | SSale | −19.7K | $70.61 | $1.39M | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Sloan Sheldon, Chief Medical Officer | SSale | −21.3K | $69.53 | $1.48M | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Sloan Sheldon, Chief Medical Officer | MExercise | +78.3K | $27.46 | $2.15M | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Burrows Scott L Chief Financial Officer | SSale | −12.5K | $71.37 | $892K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Burrows Scott L, Chief Financial Officer | MExercise | +12.5K | $14.50 | $181K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Turtle Cameron Chief Executive Officer | SSale | −300.00 | $74.96 | $22.5K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Turtle Cameron, Chief Executive Officer | SSale | −1.70K | $74.23 | $126K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Turtle Cameron, Chief Executive Officer | SSale | −3.10K | $73.14 | $227K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Turtle Cameron, Chief Executive Officer | SSale | −1.00K | $71.76 | $71.8K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Turtle Cameron, Chief Executive Officer | SSale | −3.60K | $70.77 | $255K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Turtle Cameron, Chief Executive Officer | SSale | −5.30K | $69.54 | $369K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also SYRE’s full analysis or the market-wide insider trading feed. The tabs above jump to SYRE’s other SEC data.
Source: SEC Form 4 filings for SYRE, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.